B-Myb (N-19) Antibody: sc-724

B-Myb Background Information
The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate. A second member of the Myb proto-oncogene family, B-Myb, encodes a second sequence-specific DNA binding protein. B-Myb RNA levels are low or undetectable in quiescent cells but increase at the G1/S-phase transition following mitogenic stimulation. Studies suggest that B-Myb expression rescues cells from p53-induced G1 arrest mediated by p21.